Roche acquires key gene therapy player Spark Therapeutics for $4.8bn
Roche acquired publicly traded gene therapy company Spark Therapeutics Inc. for $4.8bn, or $114.50 per share (a 128% premium), including $500mm of projected net cash at closing. Spark will continue to operate as an independent entity.
- Gene Therapy, Cell Therapy
- Large Molecule
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com